Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (14141)	11/16/2004 12:07:50 AM
From: sim1	Respond to of 52153

WSJ Article investorshub.com

To: Spekulatius who wrote (14141)	11/17/2004 12:13:21 AM
From: John Metcalf	Respond to of 52153

"Interesting to see how the same drug price per capsule went up from 5-6$ in 1998 to 30$ now." In 196X, the patient only had morning sickness. By 1998, they had Hansen's Disease (leprosy). Now they have cancer. Priced accordingly! not Some of the usual valuation concepts don't apply -- like accumulated costs of preclinical research, patent costs, litigation/settlement costs, and learning how to manufacture. The costs that do apply are FDA clearance and education in new usages. Those are waaaay steep!